Aspire Biopharma Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated April 15, 2026, details a second closing of a private placement offering of Series A Convertible Preferred Stock. The filing also reports on an amendment to the Certificate of Designation for the Preferred Stock and confirms shareholder approval obtained on April 10, 2026, to facilitate conversions exceeding 19.99% of outstanding common stock.
Key Financial Metrics and Transaction Details
- Second Closing Proceeds: The Company issued 12,500 shares of Series A Convertible Preferred Stock for aggregate gross proceeds of $10,000,000.
- Initial Closing Recap: The initial closing (February 6, 2026) involved 13,750 shares for $11,000,000 in gross proceeds, which included the conversion of $943,801 in existing debt.
- Total Offering Capacity: The Securities Purchase Agreement allows for up to 25,000 shares of Preferred Stock.
- Transaction Costs: A placement agent fee of $900,000 was paid to RBW Capital Partners, LLC.
- Liquidity Status: Post-offering, the Company reports stockholders' equity in excess of $2.5 million, meeting the minimum requirement for continued listing on The Nasdaq Capital Market.
- Conversion Terms: Preferred Stock is convertible at 80% of the lowest closing price of Common Stock over the five trading days prior to conversion, subject to a floor price of 20% of the Nasdaq Minimum Price.
Material Changes and Corporate Actions
- Capital Structure Amendment: On April 13, 2026, the Company filed a Certificate of Amendment designating 30,000 shares of Series A Convertible Preferred Stock with a stated value of $1,000 per share.
- Shareholder Approval: Shareholders approved the issuance of additional conversion shares on April 10, 2026, allowing for conversions in excess of the 19.99% beneficial ownership limit.
- Debt Conversion: The initial tranche included the conversion of approximately $943,801 of existing debt into Preferred Stock.
Outlook, Risks, and Management Commentary
Management indicates the proceeds are intended to support the Company's operations and business needs. The Company is awaiting formal confirmation from Nasdaq regarding its compliance with listing standards following the equity increase. The filing includes standard forward-looking statements warning that actual results may differ due to market conditions, cash needs, and general business risks. The Company disclaims any obligation to update these statements.
Investor Verification Checklist
- Verify the exact dilution impact on existing common shareholders given the 80% conversion discount and the 4.99% (expandable to 9.99%) beneficial ownership cap per investor.
- Confirm the formal Nasdaq listing compliance status following the reported equity increase.
- Review the full text of the Certificate of Amendment (Exhibit 3.1) for specific rights and preferences of the Series A Preferred Stock.
- Assess the remaining capacity under the Securities Purchase Agreement for future tranches of the offering.
- Examine the use of proceeds and current cash runway in subsequent filings to gauge operational sustainability.